Mounjaro vs Ozempic 2026: Which GLP-1 Is Better for Weight Loss?

What Are Ozempic and Mounjaro? Brand Names Explained

Ozempic is the brand name for semaglutide, manufactured by Novo Nordisk. It was originally approved by the FDA for type 2 diabetes management in 2017. Ozempic and Wegovy contain the same active molecule — semaglutide — at different doses. Wegovy (2.4mg weekly) is specifically approved for chronic weight management, while Ozempic (0.5–2mg weekly) is labeled for type 2 diabetes but is widely prescribed off-label for weight loss.

Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly. Approved for type 2 diabetes in 2022, it entered the obesity treatment market under the brand name Zepbound in 2023. Mounjaro and Zepbound both contain tirzepatide — the same molecule in different FDA-approved contexts.

This matters for a practical reason: the majority of people searching "Ozempic vs Mounjaro" are researching these drugs as weight loss options, even if the version they'll actually use is either Wegovy/Zepbound (brand-name obesity-approved) or compounded semaglutide/tirzepatide (affordable alternatives). All four products work through the same mechanisms as their respective molecules.

How They Work: Single vs Dual Receptor Agonist

This is the key pharmacological difference between the two drugs — and it explains why tirzepatide tends to produce greater weight loss.

Semaglutide is a GLP-1 receptor agonist. It mimics the glucagon-like peptide-1 hormone, which is naturally released from the gut after eating. When semaglutide binds to GLP-1 receptors in the brain's hypothalamus (the appetite-regulation center), it powerfully suppresses hunger, reduces food cravings, and increases satiety. It also slows gastric emptying, which means food stays in the stomach longer and extends the feeling of fullness. Additionally, it enhances insulin secretion in response to meals while suppressing glucagon, helping regulate blood sugar.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both the GLP-1 receptor (as semaglutide does) AND the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GIP is another incretin hormone that plays a role in fat storage, insulin secretion, and — when activated pharmacologically — appears to enhance the appetite-suppressing and metabolic effects of GLP-1 agonism. The combined activation creates a synergistic effect that translates into greater weight loss than a pure GLP-1 agonist can achieve alone.

Clinical Trial Results: STEP vs SURMOUNT

The most important data for comparing these two medications comes from their landmark phase 3 clinical trials, plus a direct head-to-head comparison study.

The STEP Trials (Semaglutide)

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program enrolled over 4,500 adults with obesity or overweight and at least one weight-related condition. Key results from STEP 1, published in the New England Journal of Medicine in 2021:

• Average weight loss of 14.9% of body weight over 68 weeks at the 2.4mg weekly dose
• 86.4% of participants lost at least 5% of body weight
• 69.1% lost at least 10% of body weight
• 50.5% lost at least 15% of body weight
• Placebo group lost an average of 2.4%, demonstrating the drug's independent contribution

The SELECT cardiovascular outcomes trial (2023) added a critical finding: semaglutide reduced major adverse cardiovascular events (MACE) by 20% in people with pre-existing heart disease — making it the first GLP-1 with proven cardiovascular mortality reduction independent of diabetes status.

The SURMOUNT Trials (Tirzepatide)

The SURMOUNT trial program for tirzepatide delivered some of the most striking weight loss results ever recorded in a randomized clinical trial. SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults:

• At the 5mg dose: average weight loss of 15.0%
• At the 10mg dose: average weight loss of 19.5%
• At the 15mg dose: average weight loss of 22.5% — the highest ever recorded in a phase 3 weight loss drug trial at the time
• 56.7% of participants on 15mg lost at least 20% of body weight (previously a threshold associated with bariatric surgery)
• Results were measured over 72 weeks

Side Effects: How Do They Compare?

Both semaglutide and tirzepatide share a similar side effect profile because both activate the GLP-1 receptor. The gastrointestinal system is most commonly affected, particularly during the dose-escalation phase when your body is adjusting to the medication.

Most Common Side Effects (Both Drugs)

• Nausea — most frequent complaint, typically peaks in weeks 2–8 of a new dose, then improves
• Vomiting — less common than nausea but reported in 5–15% of patients
• Diarrhea — occurs in roughly 20–30% of patients at some point during treatment
• Constipation — gastric emptying slows, and some patients shift between diarrhea and constipation
• Injection site reactions — mild redness or bruising at the injection site, typically self-resolving
• Fatigue — particularly in the first weeks of each dose increase

In SURMOUNT-1, nausea occurred in about 31–36% of tirzepatide users at the 10–15mg doses, compared to approximately 44% in the STEP 1 trial for semaglutide. However, these figures come from different trial populations and designs, making direct comparison difficult. Some providers and patients report that tirzepatide's GI side effects feel somewhat different in character — with more nausea early and less at steady state.

Dosing Schedules: What to Expect

Both medications use a gradual dose escalation protocol designed to minimize gastrointestinal side effects while the body adapts. Neither drug produces immediate maximum effects — the titration period typically takes 16–20 weeks to reach the full maintenance dose.

Cost Comparison: Brand-Name vs Compounded

Cost is the defining factor for most patients choosing between these medications — and between brand-name and compounded versions. Here is a complete breakdown of what you can expect to pay in 2026.

Brand-name costs of $1,000–$1,500 per month place these medications out of reach for the majority of Americans without generous prescription drug coverage. Medicare Part D began covering Wegovy for patients with established cardiovascular disease following the SELECT trial, but coverage for weight loss alone remains inconsistent across commercial plans.

This is why compounded alternatives have become the primary access route for most GLP-1 patients in 2026. The FDA permits licensed compounding pharmacies to prepare semaglutide and tirzepatide formulations using pharmaceutical-grade active pharmaceutical ingredients (APIs). Reputable providers like Trimi work exclusively with PCAB-accredited pharmacies and include full medical supervision — matching the clinical experience of brand-name treatment at a fraction of the cost.

Ozempic or Mounjaro: How to Choose

There is no single right answer. The best medication depends on your individual goals, health history, response, and budget. Here is a framework based on the evidence:

For a broader look at how all GLP-1 medications compare, see our best GLP-1 for weight loss 2026 guide. If cost is your main concern, our affordable GLP-1 injections guide covers every option available.

Can't Afford Brand-Name? Compounded Alternatives Through Trimi

The $1,000+ monthly price tag on Ozempic and Mounjaro is the most significant obstacle to access for the 100 million Americans living with obesity. Yet the therapeutic molecules themselves — semaglutide and tirzepatide — can be prepared by FDA-registered compounding pharmacies at a fraction of the retail cost.

Trimi is a telehealth provider that connects patients with licensed medical providers and PCAB-accredited compounding pharmacies. The process is fully online:

1. Complete your medical intake — a comprehensive health questionnaire reviewed by a licensed provider in your state
2. Receive your prescription — if approved, your provider issues a prescription and selects your starting dose
3. Medication ships to your door — compounded semaglutide or tirzepatide is prepared and shipped from a PCAB-accredited pharmacy
4. Ongoing support — your provider monitors your progress, adjusts doses, and manages any side effects

Compounded semaglutide and tirzepatide use the same active pharmaceutical ingredients as their brand-name equivalents. The clinical evidence from STEP and SURMOUNT trials — studying the exact same molecules — applies to compounded versions. For a detailed look at the evidence, see our compounded vs brand-name semaglutide comparison.

If you are comparing telehealth providers, our best online weight loss clinics 2026 guide breaks down the top platforms by cost, quality, and patient experience.

Frequently Asked Questions